Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
3.219
+0.039 (1.21%)
At close: Oct 9, 2026, 4:00 PM EDT
3.020
-0.199 (-6.17%)
After-hours: Oct 9, 2026, 5:35 PM EDT
Addex Therapeutics Employees
Addex Therapeutics had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$34,269
Profits / Employee
-$2,834,421
Market Cap
3.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -21 | -91.30% |
| Dec 31, 2023 | 23 | -1 | -4.17% |
| Dec 31, 2022 | 24 | -2 | -7.69% |
| Dec 31, 2021 | 26 | -1 | -3.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Revelation Biosciences | 9 |
| Cadrenal Therapeutics | 5 |
| Mustang Bio | 4 |
| Kairos Pharma | 4 |
ADXN News
- 1 day ago - Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial - Nasdaq
- 1 day ago - Addex Therapeutics spin-out company completes NTX-253 clinical studies - TheFly
- 1 day ago - Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia - GlobeNewsWire
- 7 days ago - Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix - Nasdaq
- 7 days ago - Addex Therapeutics Announces Executive Management Changes - GlobeNewsWire
- 10 days ago - Addex Therapeutics (ADXN): Cash Runway and Returned GABAB Rights Set the Risk - AlphaStreet
- 11 days ago - Addex Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 11 days ago - Addex Therapeutics Quarterly report: Q2 2026 - Filings